Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston
MWN-AI** Summary
Candel Therapeutics, Inc. (NASDAQ: CADL), a clinical-stage biopharmaceutical company dedicated to developing innovative multimodal biological immunotherapies for cancer treatment, is set to present at TD Cowen's 46th Annual Health Care Conference from March 2-4, 2026, in Boston. CEO Paul Peter Tak, M.D., Ph.D., will deliver the presentation on March 3, 2026, from 11:50 AM to 12:20 PM ET. Attendees can access the presentation via a live webcast on Candel’s investor relations website, with a replay available for 90 days post-event.
Candel is focused on harnessing the body’s immune system to combat cancer through two main platforms leveraging genetically modified viral constructs. Their lead product candidate, aglatimagene besadenovec (CAN-2409 or aglatimagene), comes from the adenovirus platform and has shown promising results in recent Phase 2a clinical trials for non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC). Furthermore, a pivotal Phase 3 trial for localized prostate cancer is underway under an FDA agreement. The FDA has provided multiple designations for aglatimagene, including Fast Track and Regenerative Medicine Advanced Therapy Designation for prostate cancer.
Candel's other primary candidate, linoserpaturev (CAN-3110), derived from the herpes simplex virus (HSV) platform, is currently in a Phase 1b trial for recurrent high-grade glioma. It has also garnered Fast Track and Orphan Drug Designation from the FDA. Additionally, the company's enLIGHTEN™ Discovery Platform aims to create new viral immunotherapies targeting solid tumors.
Candel Therapeutics remains committed to advancing its oncology-focused pipeline, emphasizing the potential of its therapies to improve patient outcomes in difficult-to-treat cancers. For further details, visit www.candeltx.com.
MWN-AI** Analysis
Candel Therapeutics, Inc. (Nasdaq: CADL) is poised for significant investor interest as it presents at the TD Cowen's 46th Annual Health Care Conference on March 3, 2026. This conference will serve as a platform for Candel to discuss its innovative multimodal biological immunotherapies for cancer, including its lead candidates aglatimagene and linoserpaturev, both showing promise in treating challenging malignancies.
Candel’s recent updates illuminate its advancements in clinical trials, particularly the positive outcomes for aglatimagene in phase 2a trials targeting non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC). The pivotal phase 3 trial in localized prostate cancer, receiving FDA Special Protocol Assessment, garners attention, particularly with its Fast Track and Regenerative Medicine Advanced Therapy Designations. This regulatory momentum suggests a timely pathway toward potential market authorization, which could bolster the stock’s appeal.
Investors should keep a close watch on the upcoming presentation for insights into clinical data and Candel’s strategic direction. The firm’s strong intellectual property, coupled with innovative platforms such as the enLIGHTEN™ Discovery Platform, may position it competitively within the biopharma sector. However, it is critical to remain cautious due to potential risks highlighted in their disclosures, including the uncertainties surrounding FDA approvals and the ongoing trials’ outcomes.
As Candel prepares for this important event, maintaining a well-informed perspective on both the opportunities and risks is crucial. For investors considering entering or increasing their position in CADL, strategy should emphasize a long-term horizon, recognizing the volatility inherent in biotech investments and the potential for significant rewards contingent on successful trials and regulatory approvals. Overall, Candel presents a compelling investment case within the evolving landscape of cancer therapeutics.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEEDHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will present at TD Cowen’s 46th Annual Health Care Conference, being held on March 2-4, 2026 in Boston, MA.
Presentation Details:
Date: Tuesday, March 3, 2026
Time: 11:50 AM - 12:20 PM ET
Webcast Link: TD Cowen / Candel Presentation
A webcast of the presentation will be available by selecting Events and Presentations under the News & Events tab in the Investors section at www.candeltx.com. A replay of the webcast will be archived for up to 90 days following the session date.
About Candel Therapeutics
Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene besadenovec (CAN-2409 or aglatimagene) is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the U.S. Food and Drug Administration (FDA). The FDA also granted Fast Track Designation and Regenerative Medicine Advanced Therapy Designation to aglatimagene for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease, Fast Track Designation in NSCLC, and both Fast Track Designation and Orphan Drug Designation to aglatimagene for the treatment of PDAC.
Linoserpaturev (CAN-3110) is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma, evaluating the effects of repeat linoserpaturev injections. Initial results were published in Nature and Science Translational Medicine and linoserpaturev received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
For more information about Candel, visit: www.candeltx.com.
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs; expectations regarding the therapeutic benefit of the Company’s platforms, including the ability of its platforms to improve overall survival and/or disease-free survival of patients living with difficult-to-treat, solid tumors; and expectations regarding the potential benefits conferred by regulatory designations. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company’s programs; that final data from the Company’s preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, including strategic plans for the Company’s business and product candidates; the impact of the Company’s existing and any future indebtedness on its ability to operate its business; the Company’s ability to access any future tranches under its debt facility and to comply with all of its obligations thereunder; and other risks identified in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), including the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
Investor Contact
Theodore Jenkins
Vice President, Investor Relations, and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com
Media Contact
Ben Shannon
ICR Healthcare
CandelPR@icrhealthcare.com
FAQ**
What are the key milestones that Candel Therapeutics Inc. (CADL) expects to achieve in 2026 regarding the clinical trials for aglatimagene and linoserpaturev?
How does Candel Therapeutics Inc. (CADL) plan to leverage its enLIGHTEN™ Discovery Platform to create new immunotherapies in the coming years?
What feedback does Candel Therapeutics Inc. (CADL) anticipate from investors during the TD Cowen Health Care Conference, especially regarding the recent FDA designations for its products?
How does Candel Therapeutics Inc. (CADL) address the risks associated with the clinical development of its therapies, as indicated in its forward-looking statements?
**MWN-AI FAQ is based on asking OpenAI questions about Candel Therapeutics Inc. (NASDAQ: CADL).
NASDAQ: CADL
CADL Trading
1.25% G/L:
$4.87 Last:
546,876 Volume:
$4.72 Open:
